Linda R. Duska
Research Subjects
Linda R. Duska has a total of 37 co-authors. Here are the top co-authors by number of shared publications:
A Goodman
3 shared publicationsAnnekathryn Goodman
Vincent Gynecology, Division of Gynecologic Oncology, Massachusetts General Hospital, Boston, Massachusetts, 02114
2 shared publicationsN Nikrui
2 shared publicationsA F Fuller
1 shared publicationA. B. Kornblith
1 shared publicationA. Goodman
1 shared publication
Latest Publications
- 20 May 2008
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 26 (15) , 5528
Comparison of the quality of life of early and advanced stage ovarian cancer survivors
5528 Background: No direct quality of life (QOL) comparisons have been performed based on ovarian cancer staging. The objective of this study was to compare the long-term adjustment and QOL of both early and advanced stage ovarian cancer survivors (OCS). Methods: Early and advanced OCS were identified from patient logs. All patients were >3 years from diagnosis and had no evidence of recurrent cancer. Patients were interviewed by phone or in clinic, and the following surveys were administered: EORTC QLQ-C30 (EORTC) and QLQ-OV28 (OV-28), MHI-17, CALGB sexual functioning, FACT Fatigue, Beck’s Hopelessness, Fear of Recurrence (FOR), PCL-C post-traumatic stress disorder (PTSD), Unmet Needs, FACT-Spirituality (FACT-Sp), complementary therapy use, and MOS Social Support (MOS). Overall QOL and long-term physical, mental, and sexual effects were compared between the early and advanced stage groups. Results: 58 early stage and 42 advanced pts were interviewed. Except for social functioning (EORTC-social functioning, p< .05;), there were no differences in physical symptoms, functioning and psychological state between the two groups. Anxiety when getting CA125 tested was reported by 59% of early stage and 64% of advanced stage survivors. The percent of survivors scoring at the norm or greater on the MHI Index was 71% for early stage survivors and 64% for advanced stage survivors. The following variables did not differ significantly between the two groups: overall quality of life (EORTC), fatigue (FACT), hopelessness (BECK), spirituality (FACT-Sp), social support (MOS), unmet needs and use of complementary therapy. Psychological assessment revealed that 26% of both the early and advanced OCS had scores indicative of PTSD (PCL-C). Decreased sexual interest attributed to cancer was reported by 54% of early stage and 31% of advanced stage survivors, while 40.5% early stage and 46% advanced stage survivors reported decreased sexual activity attributed to cancer. Conclusions: Long-term QOL and adjustment appear to be independent of initial stage. PTSD and sexual disinterest are important issues for OCS of both early and advanced stage patients in remission. No significant financial relationships to disclose.
- 20 May 2008
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 26 (15) , 5528
Comparison of the quality of life of early and advanced stage ovarian cancer survivors
5528 Background: No direct quality of life (QOL) comparisons have been performed based on ovarian cancer staging. The objective of this study was to compare the long-term adjustment and QOL of both early and advanced stage ovarian cancer survivors (OCS). Methods: Early and advanced OCS were identified from patient logs. All patients were >3 years from diagnosis and had no evidence of recurrent cancer. Patients were interviewed by phone or in clinic, and the following surveys were administered: EORTC QLQ-C30 (EORTC) and QLQ-OV28 (OV-28), MHI-17, CALGB sexual functioning, FACT Fatigue, Beck’s Hopelessness, Fear of Recurrence (FOR), PCL-C post-traumatic stress disorder (PTSD), Unmet Needs, FACT-Spirituality (FACT-Sp), complementary therapy use, and MOS Social Support (MOS). Overall QOL and long-term physical, mental, and sexual effects were compared between the early and advanced stage groups. Results: 58 early stage and 42 advanced pts were interviewed. Except for social functioning (EORTC-social functioning, p< .05;), there were no differences in physical symptoms, functioning and psychological state between the two groups. Anxiety when getting CA125 tested was reported by 59% of early stage and 64% of advanced stage survivors. The percent of survivors scoring at the norm or greater on the MHI Index was 71% for early stage survivors and 64% for advanced stage survivors. The following variables did not differ significantly between the two groups: overall quality of life (EORTC), fatigue (FACT), hopelessness (BECK), spirituality (FACT-Sp), social support (MOS), unmet needs and use of complementary therapy. Psychological assessment revealed that 26% of both the early and advanced OCS had scores indicative of PTSD (PCL-C). Decreased sexual interest attributed to cancer was reported by 54% of early stage and 31% of advanced stage survivors, while 40.5% early stage and 46% advanced stage survivors reported decreased sexual activity attributed to cancer. Conclusions: Long-term QOL and adjustment appear to be independent of initial stage. PTSD and sexual disinterest are important issues for OCS of both early and advanced stage patients in remission. No significant financial relationships to disclose.
- 1 November 2001
- Published by Elsevier in Gynecologic Oncology
- Vol. 83 (2) , 388-393
Endometrial Cancer in Women 40 Years Old or Younger
- 1 November 2001
- Published by Elsevier in Gynecologic Oncology
- Vol. 83 (2) , 388-393
Endometrial Cancer in Women 40 Years Old or Younger
- 1 August 1999
- Vol. 44 (8) , 669-73
Clinically significant venous thromboembolism after gynecologic surgery.
To review the incidence and outcome of clinically significant venous thromboembolism (VTE) following gynecologic surgery in a population receiving provider-specified prophylaxis. A computerized patient database was used to identify all patients diagnosed with VTE following gynecologic surgery from 1992 to 1997. Medical records were retrospectively reviewed. Clinically significant postoperative VTE was defined as pulmonary embolism or deep venous thrombosis, suggested by symptoms and physical findings, with subsequent confirmation by appropriate imaging study. Patients having VTE at the time of preoperative hospital admission and patients diagnosed with VTE after postoperative day 30 were excluded. Fifty-three patients developed postoperative VTE after > 30,000 gynecologic surgical procedures (incidence, < 1 event per 500 procedures). Forty-eight (91%) patients received some form of prophylaxis. Patients with benign disease, surgical anesthesia less than three hours and no history of prior VTE or factor V Leiden deficiency rarely developed postoperative VTE (incidence, < 1 event in 4,000 procedures). Thirteen (25%) patients had complications from anticoagulation therapy requiring prolonged hospital stay or readmission. Clinically significant VTE following gynecologic surgery is rare in the absence of malignancy, prolonged surgical anesthesia or hypercoagulation factors. Complications from anticoagulation therapy are common among gynecologic patients undergoing treatment for VTE.
- 1 August 1999
- Vol. 44 (8) , 669-73
Clinically significant venous thromboembolism after gynecologic surgery.
To review the incidence and outcome of clinically significant venous thromboembolism (VTE) following gynecologic surgery in a population receiving provider-specified prophylaxis. A computerized patient database was used to identify all patients diagnosed with VTE following gynecologic surgery from 1992 to 1997. Medical records were retrospectively reviewed. Clinically significant postoperative VTE was defined as pulmonary embolism or deep venous thrombosis, suggested by symptoms and physical findings, with subsequent confirmation by appropriate imaging study. Patients having VTE at the time of preoperative hospital admission and patients diagnosed with VTE after postoperative day 30 were excluded. Fifty-three patients developed postoperative VTE after > 30,000 gynecologic surgical procedures (incidence, < 1 event per 500 procedures). Forty-eight (91%) patients received some form of prophylaxis. Patients with benign disease, surgical anesthesia less than three hours and no history of prior VTE or factor V Leiden deficiency rarely developed postoperative VTE (incidence, < 1 event in 4,000 procedures). Thirteen (25%) patients had complications from anticoagulation therapy requiring prolonged hospital stay or readmission. Clinically significant VTE following gynecologic surgery is rare in the absence of malignancy, prolonged surgical anesthesia or hypercoagulation factors. Complications from anticoagulation therapy are common among gynecologic patients undergoing treatment for VTE.
- 1 June 1999
- Vol. 5 (6) , 1299-305
A Phase I study of continuous infusion doxorubicin and paclitaxel chemotherapy with granulocyte colony-stimulating factor for relapsed epithelial ovarian cancer.
A Phase I study of paclitaxel and doxorubicin administered as concurrent 96-h continuous i.v. infusion was performed to determine the maximum tolerated dose (MTD), principal toxicities, and pharmacokinetics of this combination in women with relapsed epithelial ovarian cancer. The paclitaxel dose was fixed at 100 mg/m2 (25 mg/m2/day for 4 days). The dose of doxorubicin was escalated from 30 mg/m2 (7.5 mg/m2/day for 4 days) in increments of 10 mg/m2 until dose-limiting toxicity was observed. All patients received granulocyte colony-stimulating factor 5 microg/kg/day prophylactically. Apparent steady-state plasma levels of both drugs were determined in the final cohort of patients treated at the MTD. A total of 17 patients received 52 cycles of therapy. The median age was 58 years, and all patients had previously received one to five different regimens (median, 2) of chemotherapy, including both platinum and paclitaxel. The treatment was tolerated well, with grade 1-2 nausea being the most frequent side effect (73% of cycles). Anemia, neutropenia, thrombocytopenia, and mucositis became dose limiting at the fourth dose level, defining the MTD of doxorubicin in this regimen as 50 mg/m2. There were four partial responses and one complete response in 15 evaluable patients. Apparent steady-state plasma concentrations (mean +/- SD) of paclitaxel and doxorubicin in the three patients treated at the MTD were 33.9 +/- 12.5 nM and 15.7 +/- 1.3 nM, respectively. Paclitaxel and doxorubicin by continuous infusion is a well-tolerated and active chemotherapy regimen for recurrent ovarian cancer.
- 1 June 1999
- Vol. 5 (6) , 1299-305
A Phase I study of continuous infusion doxorubicin and paclitaxel chemotherapy with granulocyte colony-stimulating factor for relapsed epithelial ovarian cancer.
A Phase I study of paclitaxel and doxorubicin administered as concurrent 96-h continuous i.v. infusion was performed to determine the maximum tolerated dose (MTD), principal toxicities, and pharmacokinetics of this combination in women with relapsed epithelial ovarian cancer. The paclitaxel dose was fixed at 100 mg/m2 (25 mg/m2/day for 4 days). The dose of doxorubicin was escalated from 30 mg/m2 (7.5 mg/m2/day for 4 days) in increments of 10 mg/m2 until dose-limiting toxicity was observed. All patients received granulocyte colony-stimulating factor 5 microg/kg/day prophylactically. Apparent steady-state plasma levels of both drugs were determined in the final cohort of patients treated at the MTD. A total of 17 patients received 52 cycles of therapy. The median age was 58 years, and all patients had previously received one to five different regimens (median, 2) of chemotherapy, including both platinum and paclitaxel. The treatment was tolerated well, with grade 1-2 nausea being the most frequent side effect (73% of cycles). Anemia, neutropenia, thrombocytopenia, and mucositis became dose limiting at the fourth dose level, defining the MTD of doxorubicin in this regimen as 50 mg/m2. There were four partial responses and one complete response in 15 evaluable patients. Apparent steady-state plasma concentrations (mean +/- SD) of paclitaxel and doxorubicin in the three patients treated at the MTD were 33.9 +/- 12.5 nM and 15.7 +/- 1.3 nM, respectively. Paclitaxel and doxorubicin by continuous infusion is a well-tolerated and active chemotherapy regimen for recurrent ovarian cancer.
- 1 June 1999
- Published by Elsevier in Gynecologic Oncology
- Vol. 73 (3) , 407-411
Predictors of Recurrence in Surgical Stage II Endometrial Adenocarcinoma
- 1 June 1999
- Published by Elsevier in Gynecologic Oncology
- Vol. 73 (3) , 407-411
Predictors of Recurrence in Surgical Stage II Endometrial Adenocarcinoma
- 1 October 1998
- Published by Wolters Kluwer Health
- Vol. 92 (4) , 656-658
Fertility options for patients with stages ia2 and ib cervical cancer: presentation of two cases and discussion of technical and ethical issues
Background: Ten percent to 15% of women diagnosed with cervical cancer are in their childbearing years. Traditional therapy for stage IA2 and IB lesions, radical hysterectomy, negates future fertility potential. Assisted reproductive technology might offer these women fertility options. Cases: Two cases of young nulliparous women with stage IA2 cervical cancer, who underwent ovarian stimulation and oocyte retrieval followed by radical hysterectomy, were presented to illustrate the technical difficulties of oocyte stimulation and retrieval in the setting of cervical carcinoma. Conclusion: Many issues should be considered when counseling a woman with early-stage cervical cancer about future fertility. These include ethical issues of embryo freezing and gestational surrogacy and practical issues of ovarian preservation and transposition. No current guidelines exist to identify appropriate candidates for assisted reproductive technology in this setting.
- 1 October 1998
- Published by Wolters Kluwer Health
- Vol. 92 (4) , 656-658
Fertility options for patients with stages ia2 and ib cervical cancer: presentation of two cases and discussion of technical and ethical issues
Background: Ten percent to 15% of women diagnosed with cervical cancer are in their childbearing years. Traditional therapy for stage IA2 and IB lesions, radical hysterectomy, negates future fertility potential. Assisted reproductive technology might offer these women fertility options. Cases: Two cases of young nulliparous women with stage IA2 cervical cancer, who underwent ovarian stimulation and oocyte retrieval followed by radical hysterectomy, were presented to illustrate the technical difficulties of oocyte stimulation and retrieval in the setting of cervical carcinoma. Conclusion: Many issues should be considered when counseling a woman with early-stage cervical cancer about future fertility. These include ethical issues of embryo freezing and gestational surrogacy and practical issues of ovarian preservation and transposition. No current guidelines exist to identify appropriate candidates for assisted reproductive technology in this setting.
- 1 April 1998
- Vol. 7 (2) , 363-73
Fallopian tube carcinoma.
Primary fallopian tube carcinoma represents less than 1% of all gynecologic malignancies and is therefore one of the less common malignancies of the female genital tract. Fallopian tube carcinoma is rarely diagnosed preoperatively and is often mistaken for benign pelvic disease or ovarian cancer. Compared with ovarian carcinoma, fallopian tube cancer more often presents in early stage but seems to have a worse prognosis, stage for stage. Treatment consists of surgical debulking followed by chemotherapy, adjuvant or otherwise. New studies are needed to better delineate the clinical course, prognostic factors, and appropriate chemotherapy recommendations.
- 1 April 1998
- Vol. 7 (2) , 363-73
Fallopian tube carcinoma.
Primary fallopian tube carcinoma represents less than 1% of all gynecologic malignancies and is therefore one of the less common malignancies of the female genital tract. Fallopian tube carcinoma is rarely diagnosed preoperatively and is often mistaken for benign pelvic disease or ovarian cancer. Compared with ovarian carcinoma, fallopian tube cancer more often presents in early stage but seems to have a worse prognosis, stage for stage. Treatment consists of surgical debulking followed by chemotherapy, adjuvant or otherwise. New studies are needed to better delineate the clinical course, prognostic factors, and appropriate chemotherapy recommendations.
- 1 February 1998
- Published by Wolters Kluwer Health in Obstetrics & Gynecology
- Vol. 91 (2) , 278-282
Clinical Evaluation of Atypical Glandular Cells of Undetermined Significance on Cervical Cytology
To determine the incidence of and identify risk factors for clinically significant diagnoses associated with the diagnosis on Papanicolaou test of atypical glandular cells of undetermined significance. A computer search was initiated of diagnoses of atypical glandular cells of undetermined significance at the Massachusetts General Hospital from January 1993 through December 1996. Seventy-three patients with 81 smears were identified that were seen in the Colposcopy Clinic. All cytology was reviewed. A clinically significant lesion was defined as high-grade squamous intraepithelial lesion (SIL) or worse, endocervical glandular atypia or worse, or carcinoma. The rate of diagnoses of atypical glandular cells of undetermined significance was 0.167%. All patients underwent colposcopy, and 88% underwent endocervical curettage. A clinically significant diagnosis was made in 34.2% of patients, including cancer in 8.2%. A concurrent squamous diagnosis carried a risk of clinically significant lesion of 50%, compared with a risk of 25.5% for atypical glandular cells of undetermined significance alone (P = .043). Premenopausal and postmenopausal patients were both at risk for clinically important lesions, but premenopausal patients were more likely to have a high-grade SIL (30.4% versus 7.4%, P = .04). The subtype "suggestive of reactive" was a significant negative predictor of significant lesion (odds ratio = 0.09, 95% confidence interval 0.018, 0.482) in a logistic regression model controlling for age, menopausal status, and concurrent squamous diagnosis. Atypical glandular cells of undetermined significance is an important Papanicolaou test diagnosis that needs appropriate and careful evaluation. Further studies are required to clarify areas of risk and to make triage algorithms.
- 1 February 1998
- Published by Wolters Kluwer Health in Obstetrics & Gynecology
- Vol. 91 (2) , 278-282
Clinical Evaluation of Atypical Glandular Cells of Undetermined Significance on Cervical Cytology
To determine the incidence of and identify risk factors for clinically significant diagnoses associated with the diagnosis on Papanicolaou test of atypical glandular cells of undetermined significance. A computer search was initiated of diagnoses of atypical glandular cells of undetermined significance at the Massachusetts General Hospital from January 1993 through December 1996. Seventy-three patients with 81 smears were identified that were seen in the Colposcopy Clinic. All cytology was reviewed. A clinically significant lesion was defined as high-grade squamous intraepithelial lesion (SIL) or worse, endocervical glandular atypia or worse, or carcinoma. The rate of diagnoses of atypical glandular cells of undetermined significance was 0.167%. All patients underwent colposcopy, and 88% underwent endocervical curettage. A clinically significant diagnosis was made in 34.2% of patients, including cancer in 8.2%. A concurrent squamous diagnosis carried a risk of clinically significant lesion of 50%, compared with a risk of 25.5% for atypical glandular cells of undetermined significance alone (P = .043). Premenopausal and postmenopausal patients were both at risk for clinically important lesions, but premenopausal patients were more likely to have a high-grade SIL (30.4% versus 7.4%, P = .04). The subtype "suggestive of reactive" was a significant negative predictor of significant lesion (odds ratio = 0.09, 95% confidence interval 0.018, 0.482) in a logistic regression model controlling for age, menopausal status, and concurrent squamous diagnosis. Atypical glandular cells of undetermined significance is an important Papanicolaou test diagnosis that needs appropriate and careful evaluation. Further studies are required to clarify areas of risk and to make triage algorithms.
- 1 January 1998
- Vol. 19 (5) , 441-3
Masculinizing sclerosing stromal cell tumor in pregnancy: report of a case and review of the literature.
To report a case of sclerosing stromal cell tumor of the ovary in pregnancy and to review the literature of this rare ovarian tumor. The patient's office record and hospital record were reviewed. Gross and microscopic pathology were reviewed by one gynecologic pathologist. A Medline literature search and literature review were performed. Over eighty cases of sclerosing stromal cell tumor of the ovary have been reported in the literature since the definition of this pathologic condition in 1973. Only five cases have been reported during pregnancy and only two of these resulted in maternal virilization. This report describes severe maternal virilization with birth of a non-virilized female infant. Sclerosing stromal cell tumor of the ovary can result in severe virilization via androgen production. Surgery with removal of the involved ovary is required for diagnosis and cure. Prognosis is excellent.
- 1 January 1998
- Vol. 19 (5) , 441-3
Masculinizing sclerosing stromal cell tumor in pregnancy: report of a case and review of the literature.
To report a case of sclerosing stromal cell tumor of the ovary in pregnancy and to review the literature of this rare ovarian tumor. The patient's office record and hospital record were reviewed. Gross and microscopic pathology were reviewed by one gynecologic pathologist. A Medline literature search and literature review were performed. Over eighty cases of sclerosing stromal cell tumor of the ovary have been reported in the literature since the definition of this pathologic condition in 1973. Only five cases have been reported during pregnancy and only two of these resulted in maternal virilization. This report describes severe maternal virilization with birth of a non-virilized female infant. Sclerosing stromal cell tumor of the ovary can result in severe virilization via androgen production. Surgery with removal of the involved ovary is required for diagnosis and cure. Prognosis is excellent.